Uses and methods for the treatment of liver diseases or conditions

1. A method for the palliative or restorative targeted treatment of one or more liver conditions comprising the step of orally administering a therapeutically effective amount of at least one diamidine analogue to a human patient in need thereof; wherein the liver condition is liver cancer, liver metastasis, high cholesterol, alcoholic liver disease, cirrhosis, cysts, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), fibrosis, jaundice, primary sclerosing cholangitis (PSC), hemochromatosis, primary biliary cirrhosis or Alpha-1 Antitrypsin Deficiency, wherein the diamidine analogue is pentamidine or decamidine or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the levels of the diamidine analogue are increased in the liver relative to the levels in other tissues or organs.

3. The method of claim 1 , wherein the diamidine analogue is pentamidine or a pharmaceutically acceptable salt thereof.

4. The method of claim 1 , wherein the diamidine analogue is decamidine or a pharmaceutically acceptable salt thereof.

5. The method of claim 1 , wherein the diamidine analogue is pentamidine bis(2-hydroxyethanesulfonate), pentamidine isethionate, pentamidine HCl or pentamidine tosylate.

6. The method of claim 1 , wherein the diamidine analogue is pentamidine isethionate.

7. The method of claim 1 , wherein the diamidine analogue is administered at least once daily at a dose of about 1 mg to about 3000 mg, of about 1 mg to about 2000 mg or of about 50 mg to about 700 mg.

8. The method of claim 1 , wherein the diamidine analogue is administered for more than 15, 60, 120 or 365 consecutive days.

9. The method of claim 1 , wherein the diamidine analogue is orally administered as a solid dosage form or as an instant release solid dosage form.

10. The method of claim 1 , wherein the treatment results in a reduced toxicity relative to an equivalent diamidine analogue dose administered intravenously.

11. The method of claim 1 , wherein the treatment results in a reduced kidney, heart or pancreas toxicity relative to an equivalent diamidine analogue dose administered intravenously.

12. The method of claim 1 , wherein the liver cancer is intra-hepatic bile duct cancer or hepatocarcinoma.

13. The method of claim 1 , wherein the liver metastases are liver dominant cancer metastases or liver limited cancer metastases.

14. The method of claim 1 , wherein the liver condition is alcoholic liver disease.

15. The method of claim 1 , wherein the liver condition is primary biliary cirrhosis.

16. The method of claim 1 , wherein the liver condition is NAFLD.

17. The method of claim 1 , wherein the liver condition is Alpha-1 Antitrypsin Deficiency.

18. The method of claim 1 , wherein the liver condition is primary sclerosing cholangitis (PSC).

19. The method of claim 1 , wherein the diamidine analogue is administered in combination with a further agent indicated for the treatment of the one or more liver conditions.

20. The method of claim 14 , wherein the alcoholic liver disease is alcoholic hepatitis.

21. The method of claim 14 , wherein the alcoholic liver disease is acute alcoholic hepatitis.

22. The method of claim 1 , wherein the liver condition is NASH.

23. A method for the palliative or restorative targeted treatment of non-alcoholic fatty liver disease (NAFLD) comprising the step of orally administering a therapeutically effective amount of pentamidine or a pharmaceutically acceptable salt thereof.

24. The method of claim 23 , wherein pentamidine or a pharmaceutically acceptable salt thereof is pentamidine isethionate.

25. The method of claim 23 , wherein the treatment results in a reduced toxicity relative to an equivalent pentamidine dose administered intravenously.

26. A method for the palliative or restorative targeted treatment of non-alcoholic steatohepatitis (NASH) comprising the step of orally administering a therapeutically effective amount of pentamidine or a pharmaceutically acceptable salt thereof.

27. The method of claim 26 , wherein pentamidine or a pharmaceutically acceptable salt thereof is pentamidine isethionate.

28. The method of claim 26 , wherein the treatment results in a reduced toxicity relative to an equivalent pentamidine dose administered intravenously.